Data as of May 17
| +0.04 / +0.10%|
The 7 analysts offering 12-month price forecasts for Synageva Biopharma Corp have a median target of 57.00, with a high estimate of 76.00 and a low estimate of 50.00. The median estimate represents a +42.96% increase from the last price of 39.87.
The current consensus among 8 polled investment analysts is to Buy stock in Synageva Biopharma Corp. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.